Chemotherapy of ovarian cancer

Seminars in Oncology

Volumn 11, Issue 3, 1984, Pages 251-263

  Ozols, Robert F ^a   Young, Robert C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BUTHIONINE SULFOXIMINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GESTAGEN; MELPHALAN; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; SODIUM THIOSULFATE; TAMOXIFEN CITRATE; VERAPAMIL;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; DRUG COMPARISON; DRUG THERAPY; ENDOCRINE SYSTEM; FEMALE GENITAL SYSTEM; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; PROGNOSIS; REVIEW; SURVIVAL; THERAPY;

ALTRETAMINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN ANTAGONISTS; FEMALE; FLUOROURACIL; HUMAN; MELPHALAN; METHOTREXATE; OVARIAN NEOPLASMS; PROGESTATIONAL HORMONES; TAMOXIFEN;

EID: 0021635350     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Ovarian cancer with special regard to radiotherapy
2. Clinical and histologic studies of ovarian carcinoma: Long-term followup of 900 cases
3. Radiation therapy in the management of carcinoma of the ovary
4. The chemotherapy of ovarian carcinoma
5. Chemotherapy of ovarian cancer: New approaches to treatment
6. Grading of gynecologic malignancy: Epithelial ovarian cancer
7. Epithelial carcinoma of the ovary: Prognostic importance of histologic grade
8. Histologic grade in advanced ovarian cancer
9. Ovarian carcinoma: Improved survival following abdominopelvic irradiation in patients with a completed pelvic operation
10. Advanced ovarian cancer: Correlation of histologic grade with response to therapy and survival
11. Choice of postoperative therapy based on prognostic factors
12. Treatment of ovarian carcinoma: Possibilities for progress
13. Management of ovarian carcinoma: Current concepts and future prospects
14. Malignant tumor of the ovary managed with postoperative megavoltage irradiation
15. Review of ovarian cancer at the University of Texas Center, M.D. Anderson Hospital and Tumor Institute
16. Surgical resection of bulk tumor in the primary treatment of ovarian carcinoma
17. Prospective trial of melphalan (L-PAM) versus combination chemotherapy (hexa-CAF) in ovarian adenocarcinoma
18. Combination chemotherapy (CHex-UP) with intraperitoneal maintenance in advanced ovarian adenocarcinoma
19. Advanced ovarian cancer: Brief intensive combination chemotherapy and second-look operation
20. Combination chemotherapy with Adriamycin-cyclophosphamide for advanced ovarian carcinoma
21. Chemotherapy for stage III–IV epithelial ovarian cancer with cisplatin, Adriamycin, and cyclophosphamide: A preliminary report
22. Second-look operations in ovarian cancer
23. Second-look laparotomy in the management of gynecologic malignancies
24. L-PAM vs cyclophosphamide, hexamethylmelamine, and 5-fiuorouracil (CHF) for advanced ovarian cancer
25. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease
26. Cyclophosphamide, hexamethylmelamine, Adriamycin, and diamminedichloroplatinum, “CHAD” versus melphalan for advanced ovarian cancer
27. Follow-up on a randomized trial of melphalan vs melphalan plus hexamethylmelamine vs Adriamycin plus cyclophosphamide in advanced ovarian adenocarcinoma
28. A prospective and randomized trial comparison of melphalan vs Adriamycin-melphalan in advanced ovarian carcinoma
29. Cyclophosphamide plus cis-platinum in combination: Treatment program for stage III or IV ovarian carcinoma
30. Medical Research Council study on chemotherapy in advanced ovarian cancer
31. Advanced ovarian carcinoma. A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)
32. Combination chemotherapy for alkylator-resistant ovarian carcinoma: A preliminary report of a Southwest Oncology Group trial
33. Phase II trial of cyclophosphamide, hexamethylmelamine, Adriamycin, and cis-dichlorodiammineplatinum (II) combination chemotherapy in advanced ovarian carcinoma
34. The CHAD and HAD regimens in advanced ovarian cancer: Combination chemotherapy including hexamethylmelamine, Adriamycin, and cis-dichlorodiammineplatinum (II)
35. Combination chemotherapy for ovarian carcinoma with cyclophosphamide, Adriamycin, and cis-dichlorodiammineplatinum (II) after failure of initial chemotherapy
36. The role of adjuvant therapy in Stage I ovarian cancer
37. Treatment of ovarian cancer
38. Comparison of external radiotherapy and chemotherapy in ovarian cancer
39. Staging laparotomy in early ovarian cancer
40. Early stage ovarian cancer: Preliminary results of randomized trials after comprehensive initial staging
41. A strategy for effective management of early ovarian carcinoma
42. Acute leukemia after alkylating agent therapy in ovarian cancer
43. The multimodal approach to the treatment of stage III ovarian carcinoma
44. Preoperative irradiation in stage III carcinoma of the ovary
45. Advanced ovarian carcinoma: Interaction of surgical treatment and chemotherapy with cyclophosphamide, Adriamycin, and cisdiamminedichloroplatinum
46. Whole abdominal and pelvic irradiation in patients with minimal disease at second look surgical reassessment for ovarian carcinoma
47. Advanced minimal residual ovarian carcinoma: Abdominopelvic irradiation following combination chemotherapy
48. High volume intraperitoneal chemotherapy (“Belly Bath”) for ovarian cancer
49. Phase I and pharmacologic studies of 5-fluorouracil administered intraperitoneally
50. Phase I and pharmacologic studies of Adriamycin administered intraperitoneally to patients with ovarian cancer
51. Intraperitoneal cisplatinum therapy of ovarian cancer
52. Intraperitoneal cisplatin with systemic thiosulphate protection
53. High dose platinum for the treatment of refractory ovarian cancer
54. Use of high-dose cisplatinum (II) following failure of previous chemotherapy for advanced carcinoma of the ovary
55. High dose cisplatin in hypertonic saline
56. Alterations in the toxicity of cis-dichlorodiammine platinum II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration
57. Direct cloning of human ovarian carcinoma cells in agar
58. In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy
59. A critical appraisal of the “human tumor stem cell assay.”
60. Direct cloning of human ovarian cancer in soft agar: Clinical limitations and pharmacologic applications
61. Second trial drugs in ovarian cancer
62. Prospective clinical trial of a human tumor cloning system
63. Pleiotropic phenotype of colchicine resistant CHO cells: Cross resistance and collateral sensitivity
64. Resistance and cross resistance of human ovarian cancer cell lines to Adriamycin, melphalan, and irradiation
65. Reversal of Adriamycin resistance by verapamil in human ovarian cancer
66. Verapamil plus Adriamycin in refractory ovarian cancer: Design of a clinical trial on basis of reversal of adriamycin resistance in human ovarian cancer cell lines
67. Melphalan resistance in human ovarian cancer: Potentiation of melphalan cytotoxicity by nutritional and pharmacological depletion of intracellular glutathione levels
68. A unique intraperitoneal model of human ovarian cancer
69. Progesterone therapy for ovarian carcinoma
70. High dose medroxy progesterone acetate for the treatment of advanced ovarian carcinoma
71. Progestin therapy for advanced ovarian cancer a phase II Eastern Cooperative Oncology Group Trial
72. Advanced ovarian carcinoma: Response to antiestrogen therapy
73. Tamoxifen therapy for advanced ovarian cancer
74. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors
75. Müllerian duct regression in the embryo correlated with cytotoxicity against human ovarian cancer
76. Müllerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice
77. Cancer Statistics, 1984